PMID- 37533592
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230804
IS  - 1687-966X (Print)
IS  - 1687-9678 (Electronic)
VI  - 2023
DP  - 2023
TI  - The m(6)A Reader YTHDF1 Accelerates the Osteogenesis of Bone Marrow Mesenchymal 
      Stem Cells Partly via Activation of the Autophagy Signaling Pathway.
PG  - 5563568
LID - 10.1155/2023/5563568 [doi]
LID - 5563568
AB  - N6-methyladenosine (m(6)A) mRNA methylation has emerged as an important player in 
      many biological processes by regulating gene expression. As a crucial reader, 
      YTHDF1 usually improves the translation efficiency of its target mRNAs. However, 
      its roles in bone marrow mesenchymal stem cells (BMSCs) osteogenesis remain 
      largely unknown. Here, we reported that YTHDF1, an m(6)A reader, is highly 
      expressed during osteogenic differentiation of BMSCs. Upregulation of YTHDF1 
      increased osteogenic differentiation and proliferation capacity of BMSCs. 
      Accordingly, downregulation of YTHDF1 inhibited osteogenic differentiation and 
      proliferation capacity. Possible underlying mechanisms were explored, and 
      analysis revealed that YTHDF1 could affect autophagy levels, thus regulating 
      osteogenesis of BMSCs. In an in vivo study, we found that upregulation of YTHDF1 
      accelerates fracture healing with elevated bone volume fraction and trabecular 
      thickness. Taken together, our study revealed that m(6)A reader YTHDF1 
      accelerates osteogenic differentiation of BMSCs partly via the autophagy 
      signaling pathway. These findings reveal a previously unrecognized mechanism 
      involved in the regulation of BMSCs osteogenesis, providing new ideas and target 
      sites for the treatment of fracture.
CI  - Copyright (c) 2023 Xiang Gao et al.
FAU - Gao, Xiang
AU  - Gao X
AUID- ORCID: 0000-0002-4557-8231
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
AD  - Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, Zhejiang, China.
FAU - Wang, Jian
AU  - Wang J
AUID- ORCID: 0009-0005-2983-0993
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
AD  - Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, Zhejiang, China.
FAU - Wang, Yibo
AU  - Wang Y
AUID- ORCID: 0000-0002-2941-7841
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
AD  - Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, Zhejiang, China.
FAU - Li, Weixu
AU  - Li W
AUID- ORCID: 0000-0002-6742-3230
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
AD  - Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, Zhejiang, China.
FAU - Pan, Zhijun
AU  - Pan Z
AUID- ORCID: 0000-0002-4618-5990
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
AD  - Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20230725
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC10393526
COIS- The authors declare that the research was conducted in the absence of commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/08/03 06:43
MHDA- 2023/08/03 06:44
PMCR- 2023/07/25
CRDT- 2023/08/03 03:53
PHST- 2023/03/07 00:00 [received]
PHST- 2023/06/04 00:00 [revised]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/08/03 06:44 [medline]
PHST- 2023/08/03 06:43 [pubmed]
PHST- 2023/08/03 03:53 [entrez]
PHST- 2023/07/25 00:00 [pmc-release]
AID - 10.1155/2023/5563568 [doi]
PST - epublish
SO  - Stem Cells Int. 2023 Jul 25;2023:5563568. doi: 10.1155/2023/5563568. eCollection 
      2023.